Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: Analysis of Canadian open-label studies

Child and Adolescent Psychiatry and Mental Health

Volumn 5, Issue , 2011, Pages

  Dickson, Ruth A ^a,b   Maki, Ellen ^c   Gibbins, Christopher ^d   Gutkin, Stephen W ^e   Turgay, Atilla ^f   Weiss, Margaret D ^d  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c Analytica Statistical Consulting   (Canada)

^d CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^e Rete Biomedical Communications Corp   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Attention deficit hyperactivity disorder atomoxetine; Drug therapy; Remission; Response; Treatment outcomes

Indexed keywords

ATOMOXETINE; PLACEBO;

ANALYTIC METHOD; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER RATING SCALE IV PARENT VERSION INVESTIGATOR ADMINISTERED AND SCORED SCALE; CHILD; CLINICAL GLOBAL IMPRESSIONS ATTENTION DEFICIT HYPERACTIVITY DISORDER SEVERITY SCALE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SURVIVAL; SYMPTOM; TREATMENT RESPONSE;

EID: 79955783537     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-5-14     Document Type: Article

References (24)

1. Canadian ADHD Resource Alliance (CADDRA) Canadian ADHD Practice Guidelines 2011, Accessed April 25, 2011, Canadian ADHD Resource Alliance (CADDRA)., http://www.caddra.ca/cms4/
2. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2003, 2:104-113. 1525078, 16946912.
3. Pliszka S, . AACAP Work Group on Quality Issues Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007, 46:894-921. AACAP Work Group on Quality Issues.
4. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004, 114:e1-e8. 10.1542/peds.114.1.e1, 15231966.
5. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, . Atomoxetine ADHD Study Group Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001, 108:E83. 10.1542/peds.108.5.e83, 11694667, Atomoxetine ADHD Study Group.
6. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002, 159:1896-1901. 10.1176/appi.ajp.159.11.1896, 12411225.
7. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002, 63:1140-1147. 10.4088/JCP.v63n1209, 12523874.
8. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005, 44:647-655. 10.1097/01.chi.0000163280.47221.c9, 15968233.
9. Steele M. Introduction to remission in ADHD: raising the bar. Clin Ther 2006, 28:1879-1881.
10. Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field?. Clin Ther 2006, 28:1892-1908. 10.1016/j.clinthera.2006.11.006, 17213010.
11. DuPaul G, Reid R, Power T, Anastopoulos A. ADHD rating scale-IV: checklists, norms, and clinical interpretations. 1998, New York, NY: Guilford Publications, Inc.
12. Guy W. ECDEU: assessment manual for psychopharmacology, revised 1976, Rockville, MD: US Dept. of Health, Education, and Welfare.
13. Dickson R, Lee B, Turgay A, Chang S, White H, Davis L, Wasdell M, Yoshioka A, Weiss M. Atomoxetine treatment of ADHD: symptomatic, academic, cognitive, and functional outcomes. Presented at the American Academy of Child and Adolescent Psychiatry, 54th Annual Meeting, Boston, MA 2007,
14. Maziade M, Rouleau N, Lee B, Rogers A, Davis L, Dickson R. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol 2009, 19:709-718. 10.1089/cap.2008.0166, 20035589.
15. Dickson RA, Jackiewicz G, Khattak S, Gilchrist W, Szombathy S, Brunner E. Change in ADHD symptoms and functional outcomes in Canadian children during 3 months of atomoxetine treatment. Presented at the 27th Annual Conference of the Canadian Academy of Child and Adolescent Psychiatry, Montréal, Québec 2007,
16. American Psychiatric Association (APA) Diagnostic and statistical manual of mental disorders text revision (DSM-IV-TR) 2000, Washington, DC: APA, American Psychiatric Association (APA).
17. Turnbull BW. The empirical distribution function with arbitrarily grouped, censored, and truncated data. J Royal Stat Soc Series B 1976, 38:290-295.
18. Lawless J. Statistical Models and Methods for Lifetime Data 2003, Hoboken, NJ: John Wiley and Sons.
19. Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin 2009, 25:2745-2754.
20. Svanborg P, Thernlund G, Gustafsson PA, Hagglof B, Poole L, Kadesjo B. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. Eur Child Adolesc Psychiatry 2009, 18:240-249. 10.1007/s00787-008-0725-5, 19156355.
21. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D, . Atomoxetine/Methylphenidate Comparative Study Group Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008, 165:721-730. 10.1176/appi.ajp.2007.05091676, 18281409, Atomoxetine/Methylphenidate Comparative Study Group.
22. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 2005, 22:498-512. 10.1007/BF02849870, 16418159.
23. Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL, Wigal TL, Kollins SH, Clark TM, Mays DA, Zhang Y, Tulloch SJ. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005, 9:275-289. 10.1177/1087054705281121, 16371674.
24. Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry 2009, 48:511-518. 10.1097/CHI.0b013e31819c55b2, 19318988.